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Step Therapy: Legal, Ethical, and Policy 
Implications of a Cost-Cutting Measure 
SHARONA HOFFMAN 
ABSTRACT 
The very high and ever-increasing costs of medical care in the United States are 
well-recognized and much discussed. Health insurers have employed a variety of 
strategies in an effort to control their expenditures, including one that is common but 
has received relatively little attention: step therapy. Step therapy programs require 
patients to try less expensive treatments and find them to be ineffective or otherwise 
problematic before the insurer will approve a more high-priced option. This article is 
the first law journal piece dedicated to analyzing this important cost control measure. 
This article explores the strengths and weaknesses of step therapy and its legal and 
ethical implications. It argues that in some cases, step therapy reduces insurers’ drug 
costs in the short term but causes significant harm to patients that ultimately results in 
both human suffering and increased long-term health care costs. Some insurers are 
also less than transparent with patients about their programs, adhere to one-size-fits-
all approaches that ignore nuanced clinical and economic evidence, and implement 
their policies in a discriminatory way. This article examines how several states have 
responded to step therapy through legislation and discusses review mechanisms that 
federal law provides for adverse insurance decisions. This article concludes with a 
detailed set of recommendations. These include legislative interventions to ensure that 
step therapy programs are sufficiently flexible and responsive to patients’ individual 
needs and measures to enhance transparency and expeditiously address emerging 
scientific and economic evidence. 
INTRODUCTION 
My husband Andy was diagnosed with Parkinson’s disease at the age of fifty-five 
in October of 2013. Happily, he is managing his disease well and still works full-time 
as a professor of computer science. He exercises regularly and takes several 
medications. We are hopeful that the disease will progress slowly and that there are 
still many good years ahead. 
Imagine our dismay when, in late 2016, our pharmacy benefit manager (PBM)1 
informed us that it was denying coverage for the drug that Andy found most helpful 
and that it had previously covered. The PBM’s explanation was as follows: 
 
    Edgar A. Hahn Professor of Law and Professor of Bioethics, Co-Director of Law-Medicine Center, 
Case Western Reserve University School of Law; B.A., Wellesley College; J.D., Harvard Law School; 
LL.M. in Health Law, University of Houston; S.J.D. in Health Law, Case Western Reserve University. I 
thank Maxwell Mehlman and Jacqueline Lipton for their very helpful comments on prior drafts. 
1 A pharmacy benefits manager administers the drug benefit program for a health plan. It processes 
and pays prescription drug claims, negotiates with manufacturers for lower drug prices, and can employ 
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Your plan approved criteria covers this drug when the patient has tried 
and had an inadequate treatment response, intolerance, or contraindication 
to all formulary alternatives for the given diagnosis (or to at least 1 agent 
within each of a given class of agents when more than 1 class is available 
for the diagnosis), or when the drug is the only product the patient can use 
for their condition. Your use of this drug does not meet the requirement.2 
This was our introduction to step therapy, a policy that requires patients to take 
cheaper drugs first and find that they fail before being approved for more expensive 
treatments.3 After calling several pharmacies, I determined that the drug, at Andy’s 
dosage, would cost us over $8,000 a year if we were to pay out-of-pocket. Because 
Andy had already tried several less effective therapies, we undertook an appeal process 
and were ultimately rewarded with a temporary reprieve. However, our PBM has 
reserved the right to revisit the matter in the future. 
This article is the first law journal piece dedicated to the step therapy phenomenon. 
Unbeknownst to most patients, step therapy is pervasive in health insurance plans.4 
Step therapy programs raise a variety of compelling legal and ethical challenges that 
are analyzed in this paper. Although it is often PBMs that institutes step therapy 
programs (insurers can contract with external PBMs or have their own, internal ones),5 
the remainder of the article will refer to those who operate step therapy programs 
collectively as “insurers” for the sake of simplicity. 
Insurers can hardly be blamed for undertaking initiatives to control their 
expenditures. Indisputably, the United States suffers from a dramatic and worrisome 
rise in health care costs.6 
The question is whether step therapy programs are a sound solution. There is no 
categorical answer to this query. For some patients, step therapy requirements are 
reasonable and meet their treatment needs. However, it is not uncommon for step 
therapy to provide patients with inadequate care that can cause serious harm. 
Eitan Kling-Levine, an ulcerative colitis patient, related in a Boston Globe opinion 
piece that his insurer required that he fail several drugs during a six-month period 
before approving the physician’s chosen biologic therapy.7 During that six-month 
 
other cost-saving mechanisms. PBMs thus act as intermediaries between the insurer and pharmacies. See 
Joanna Shepherd, The Fox Guarding the Henhouse: The Regulation of Pharmacy Benefit Managers by a 
Market Adversary, 9 NW. J. L. & SOC. POL’Y, 1, 7–9 (2013); Jessica Wapner, Understanding the Hidden 
Villain of Big Pharma: Pharmacy Benefit Managers, NEWSWEEK, Mar. 17, 2017, 
http://www.newsweek.com/big-pharma-villain-pbm-569980 [https://perma.cc/PPT7-6VTT]. For additional 
information about PBMs see infra note 86 and accompanying text. 
2 Notice of Adverse Determination to H.Podgurski (Nov. 15, 2016) (on file with author). 
3 Rahul K. Nayak & Steven D. Pearson, The Ethics of ‘Fail First’: Guidelines and Practical Scenarios 
for Step Therapy Coverage Policies, 33 HEALTH AFF. 1179, 1779 (2014). 
4 See infra note 23 and accompanying text. 
5 Wapner, supra note 1 (stating that insurance giant United Healthcare has its own PBM that is called 
OptumRx). 
6 See infra Part I. B; Doug Holtz-Eakin, More Government Is Not the Remedy for High Drug Prices, 
FORBES, Mar. 2, 2017, https://www.forbes.com/sites/realspin/2017/03/02/more-government-is-not-the-
remedy-for-high-drug-prices/#6d7691082bb5 [https://perma.cc/T4B9-GQ5Y]. 
7 Eitan Kling-Levine, A Medical Therapy That’s No Therapy at All, BOSTON GLOBE (July 23, 2016), 
https://www.bostonglobe.com/opinion/2016/07/23/medical-therapy-that-therapy-all/wttF75QVPmvEXWJ
knhW6MO/story.html [https://perma.cc/P2YS-KQ9C]. Biological therapy “involves the use of living 
organisms, substances derived from living organisms, or laboratory-produced versions of such substances 
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period, his health deteriorated to such an extent that he ultimately had his colon 
surgically removed. He speculates that he might have been able to avoid this radical 
surgery and considerable pain and suffering had he been allowed to take the biologic 
as soon as his doctor prescribed it.8 Kathleen Arntsen, a glaucoma9 patient, stated in 
an interview that she was required to try two inexpensive drugs over seven weeks 
before being allowed to use the Travatan Z eye drops that her physician had initially 
prescribed.10 She experienced swelling, increased pressure, and loss of vision in her 
eye and, at the time of writing, was considering having the eye removed because it 
continued to hurt.11 She too believes that the delay contributed to her poor outcome.12 
For patients, receiving the medication that is most effective for them and causes the 
least severe side effects can make the difference between being homebound and being 
able to work, care for one’s family, and enjoy life. Working can engender not only 
financial stability, but also strong self-esteem, social ties, and a sense of purpose, all 
of which contribute to good mental and even physical health.13 
When an insurer denies coverage for a drug that a physician selects as the best fit 
for the patient (in Andy’s case, a drug that he has taken successfully for many months), 
the patient can suffer severe consequences, such as adverse reactions to a different 
drug, complications, and deteriorating health.14 Insurers, in turn, ultimately cover the 
cost of treatments for these adverse outcomes.15 Patients who wish to dispute the denial 
must ask physicians to assist them with an appeal and hope that their doctors have the 
time and the gumption to do so. Handling such requests is a burdensome task for which 
physicians do not directly get paid.16 
Step therapy thus impacts multiple parties with often conflicting agendas. Patients 
seek treatments that are as safe and effective as possible, want comprehensive 
insurance coverage, and often expect to be able to choose among different treatment 
 
to treat disease.” Biological Therapies for Cancer, NAT’L CANCER INST., https://www.cancer.gov/about-
cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet#q1 [https://perma.cc/7QYX-ANEY] (last 
visited June 12, 2013). For example, a form of cancer treatment called immunotherapy uses “vaccines or 
bacteria to stimulate the body’s immune system to act against cancer cells.” Id. 
8 Kling-Levine, supra note 7. 
9 Glaucoma is a disease that damages the eye’s optic nerve and is usually associated with fluid build- 
up in the front part of the eye that increases eye pressure. Kierstan Boyd, What Is Glaucoma? AM. ACAD. 
OPHTHALMOLOGY (Mar. 1, 2017), https://www.aao.org/eye-health/diseases/what-is-glaucoma [https://
perma.cc/9W7Z-KYC4]. 
10 Bob Tedeschi, Are Insurance Policies Saving Patients Money, or Keeping Them from the 
Treatment They Need?, STAT, Aug. 22, 2016, https://www.statnews.com/2016/08/22/step-therapy-
patients-insurance-treatments/ [https://perma.cc/TG9T-FJFX]. 
11 Id. 
12 Id. 
13 WORLD HEALTH ORG. & INT’L LABOR ORG., MENTAL HEALTH AND WORK: IMPACT, ISSUES AND 
GOOD PRACTICES 5 (2000), http://www.who.int/mental_health/media/en/712.pdf [https://perma.cc/2K6Q-
RJFS] (“Although it is difficult to quantify the impact of work alone on personal identity, self-esteem and 
social recognition, most mental health professionals agree that the workplace environment can have a 
significant impact on an individual’s mental well-being.”). 
14 See infra Part I. C. 
15 Id. 
16 PFIZER, STEP THERAPY AND FAIL FIRST POLICIES BACKGROUNDER (Oct. 2011), 
https://failfirsthurts.org/ffh/wp-content/uploads/2012/10/WWP-Purple-Paper-Step-Therapy-and-Fail-First-
Policies.pdf [https://perma.cc/DB59-U8UD]. 
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options. Insurers have a duty to serve their enrollees’ health needs but wish to save 
costs whenever practicable. Physicians devote themselves to patient care, worry about 
patient satisfaction and their professional reputations,17 and wish to minimize 
cumbersome administrative work. Also influential are pharmaceutical companies that 
market their products aggressively to health care providers and to patients through 
direct-to-consumer advertising.18 
Step therapy, therefore, has more complicated implications than initially meet the 
eye. Step therapy policies should be carefully designed to achieve cost savings while 
remaining flexible, responsive to patients’ needs, and consistent with relevant clinical 
data. Insurers should be careful not to strive single-mindedly to reduce short-term costs 
at the expense of ignoring patients’ overall well-being, physicians’ treatment goals, 
and the prospect of increased long-term expenditures. 
This article proceeds as follows. Part I provides background information about step 
therapy. It also discusses the need for cost control measures in light of skyrocketing 
pharmaceutical prices. In addition, it analyzes whether step therapy is effective in 
meeting cost reduction goals. Part II argues that step therapy raises several legal and 
ethical concerns. These include lack of transparency, inflexibility that may disregard 
emerging evidence from precision medicine and other research initiatives, and 
discrimination. Part III assesses state and federal legislation that is relevant to step 
therapy. Several states have passed step therapy statutes that outline the circumstances 
under which insurers must grant waivers and require that they do so expeditiously 
upon receiving appropriate requests. Federal law in the form of the Employee 
Retirement Income Security Act of 1974 (ERISA),19 the Patient Protection and 
Affordable Care Act (ACA),20 and the Medicare Prescription Drug, Improvement and 
Modernization Act of 2003 (MMA)21 also feature mechanisms for challenging adverse 
insurance decisions and for the review process that insurers must implement. Part IV 
develops recommendations to address concerns about step therapy. It proposes, first, 
that all states enact step therapy laws; second, that federal law specifically address step 
therapy programs; third that insurers improve transparency by disseminating clear 
information about step therapy requirements in print and on their websites; fourth, that 
expert panels such as insurers’ pharmacy and therapeutics committees monitor and 
incorporate up-to-date scientific and financial evidence into their policies; and fifth, 
that insurers implement step therapy programs in a non-discriminatory way. Part V 
concludes the article. 
 
17 James F. Sweeney, Physicians Dissatisfied with Patient Satisfaction Surveys, MED. ECON., Nov. 
10, 2016, http://medicaleconomics.modernmedicine.com/medical-economics/news/physicians-dissatisfied-
patient-satisfaction-surveys [https://perma.cc/3LFT-2NY4]. 
18 The Impact of Direct-to-Consumer Advertising, FOOD & DRUG ADMIN., https://www.fda.gov/
drugs/resourcesforyou/consumers/ucm143562.htm [https://perma.cc/H73E-WJLA] (last updated Oct. 23, 
2015). 
19 29 U.S.C. §§ 1001, 1461 (2010). 
20 42 U.S.C. §§ 18001 et seq. (2010). 
21 Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 
117 Stat. 2066 (codified in scattered sections of 26 and 42 U.S.C.). 
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I. STEP THERAPY: WHAT, WHY, AND WHEN 
Step therapy is a common cost reduction tool of which many insurance enrollees 
are unaware. This Part explains step therapy, discusses the need for cost control 
measures, and analyzes whether step therapy is effective at reducing medical costs. 
A. Step Therapy Basics 
Step therapy, also called “fail first” policies, require patients to try less expensive 
treatments and find them to be ineffective or otherwise problematic before the insurer 
will approve a more costly option.22 According to the American Academy of 
Dermatology, in 2010, almost sixty percent of commercial insurers had implemented 
step therapy and, as of 2014, seventy-five percent of large employers had insurance 
plans with step therapy.23 Some Medicare Part D plans utilize step therapy as well.24 
In some cases, step therapy programs require patients to try one or more generic 
drugs25 before brand name medications are approved.26 In other cases, insurers 
mandate that patients try a class of drugs that is less costly before allowing a switch to 
a more expensive class.27 
Some insurers publish lists of drugs that are subject to step therapy. Insurers often 
require step therapy for drugs to treat the following conditions: allergies, asthma, 
attention deficit hyperactivity disorder, depression, diabetes, gastrointenstinal 
problems, glaucoma, high cholesterol, high blood pressure, insomnia, menopause, 
multiple sclerosis, osteoporosis, pain, Parkinson’s disease, psoriasis, rheumatoid 
arthritis, and more.28 Other insurers provide patients with only a generic description 
of step therapy.29 Even detailed websites, however, can be difficult to navigate, and 
patients and physicians are very unlikely to scour the insurer’s website before deciding 
on a treatment plan. 
 
22 Nayak & Pearson, supra note 3, at 1779. 
23 Step Therapy Legislation, AM. ACAD. DERMATOLOGY, https://www.aad.org/advocacy/state-
policy/step-therapy-legislation [https://perma.cc/L6X2-3PAD] (last visited May 1, 2017); see also Step 
Therapy: The Red Tape between You and Your Meds, NAT’L PSORIASIS FOUND., 
http://www.steptherapyinfo.com/ [https://perma.cc/W6M3-TUP4] (last visited June 1, 2017). 
24 What Is Step Therapy in Medicare Part D?, Q1MEDICARE.COM, https://q1medicare.com/q1group/
MedicareAdvantagePartDQA/FAQ.php?faq=What-is-Step-Therapy-in-Medicare-Part-D-&faq_id=200&
category_id=1 [https://perma.cc/554C-N6NG] (last visited May 1, 2017). 
25 Generic drugs are less expensive “copies of brand-name drugs and are the same as those brand 
name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics 
and intended use.” Generic Drugs, FOOD & DRUG ADMIN., https://www.fda.gov/Drugs/resourcesforyou
/consumers/buyingusingmedicinesafely/understandinggenericdrugs/default.htm [https://perma.cc/8BG4-
8UF4] (last updated April 26, 2017). 
26 Michael A. Fischer & Jerry Avorn, Step Therapy–Clinical Algorithms, Legislation, and Optimal 
Prescribing, 317 J. AM. MED. ASS’N. 801, 801 (2017). 
27 Id. 
28 BLUECROSS BLUESHIELD OF OKLA., STEP THERAPY: WHAT YOU NEED TO KNOW, 
https://www.bcbsil.com/pdf/Group_Pharmacy_Step_Therapy_Member_Flier.pdf [https://perma.cc/4BM2-
3PDC] (last visited Dec. 28, 2017); MEDIMPACT HEALTHCARE SYS., PEEHIP STEP THERAPY LIST, 
http://www.rsa-al.gov/uploads/files/Step_Therapy_List.pdf [https://perma.cc/E3ZE-UPX3] (last revised 
Oct. 1, 2015). 
29 See, e.g., CVS CAREMARK, STEP THERAPY (2017) (on file with author) (“Even though your doctor 
may prescribe one medicine, treatment guidelines may recommend trying alternative therapy first. If that 
alternative treatment isn’t effective, you will be eligible for the medicine you were originally prescribed.”). 
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B. The Need for Cost Control Measures 
Insurers’ desire to implement cost control measures is understandable. Prescription 
drug prices rose 10.9 percent in 2014 and another ten percent in 2015.30 According to 
the AARP, “[t]he average cost for a year’s supply of medication for someone with a 
chronic illness has more than doubled since 2006 to over $11,000.”31 The costs of 
some drugs such as EpiPens and Daraprim have notoriously risen far more 
precipitously than that. The price of EpiPens, which treat severe allergic reactions, 
rose from $100 for a two-pack in 2009 to $608 in 2016.32 Turing Pharmaceuticals’ 
embattled chief executive Martin Shkreli raised the price of Daraprim, a drug to treat 
infections caused by parasites, by more than 4,000 percent from $18 a pill to $750 a 
pill.33 
Furthermore, insurers worry that some prescribing decisions are driven by 
pharmaceutical companies’ intensive marketing efforts.34 Whether because of 
advertising or for other reasons, some physicians do not follow experts’ 
recommendations for first-choice drugs that are relatively inexpensive.35 For example, 
one study showed that thirty-five percent of newly diagnosed diabetes patients did not 
receive metformin, recommended as the initial treatment choice in clinical 
guidelines.36 A 2013 exposé in the Washington Post revealed that many doctors 
injected macular degeneration patients with Lucentis at a cost of approximately $2,000 
an injection rather than with Avastin, which would cost a mere $50,37 though not all 
physicians agree about which drug is the better alternative.38 
Step therapy is one of several cost-saving measures that insurers employ. Examples 
of other cost-saving techniques are medical necessity determinations, requirements for 
 
30 Brady Dennis, Prescription Drug Prices Jumped More than 10 Percent in 2015, WASH. POST (Jan. 
11, 2016), https://www.washingtonpost.com/news/to-your-health/wp/2016/01/11/prescription-drug-prices-
jumped-more-than-10-percent-in-2015/?utm_term=.9c950115de36 [https://perma.cc/V334-PYHE]. 
31 Jo Ann Jenkins, Let’s Cut Drug Costs, 58 AARP BULL. 24 (May 2017). 
32 Daniel Kozarich, Mylan’s EpiPen Pricing Crossed Ethical Boundaries, FORTUNE, Sept. 27, 2016, 
http://fortune.com/2016/09/27/mylan-epipen-heather-bresch/ [https://perma.cc/P363-BNJ3]. 
33 Ariana Eunjung Cha, CEO Martin Shkreli: 4,000 Percent Drug Price Hike is ‘Altruistic,’ not 
Greedy, WASH. POST (Sep. 22, 2015), https://www.washingtonpost.com/news/to-your-health/wp/2015/09
/22/turing-ceo-martin-shkreli-explains-that-4000-percent-drug-price-hike-is-altruistic-not-greedy/?utm_
term=.61a1ccfc50e3 [https://perma.cc/3ZAK-8F96]. 
34 Fischer & Avorn, supra note 26, at 802. 
35 Id. 
36 Nihar R. Desai, Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality 
and Cost Implications, 125 AM. J. MED. 302.el (Mar. 2012), http://www.amjmed.com/article/S0002-9343
(11)00651-6/fulltext [https://perma.cc/N8ED-YSB4]. 
37 Peter Whoriskey & Dan Keating, An Effective Eye Drug is Available for $50 But Many Doctors 
Choose a $2,000 Alternative, WASH. POST (Dec. 7, 2013) https://www.washingtonpost.com
/business/economy/an-effective-eye-drug-is-available-for-50-but-many-doctors-choose-a-2000-alternative
/2013/12/07/1a96628e-55e7-11e3-8304-caf30787c0a9_story.html?utm_term=.315eedac0a1d 
[https://perma.cc/4YGH-XREA]. Macular degeneration is an eye disease, and the drugs are used to prevent 
blindness. Id. 
38 Macular Degeneration P’ship, Lucentis vs. Avastin, AMD (Nov. 2013), http://www.amd.org
/lucentis-vs-avastin/ [https://perma.cc/J8J8-Y6TM] (noting that FDA has not approved Avastin for use in 
the eye (it is approved to treat colon cancer) but that it is commonly used and has been shown by most 
studies to be as safe and effective as Lucentis). 
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prior authorization, quantity limits, and tiering.39 Medical necessity determinations 
deny coverage based on an insurer’s determination that the prescribed therapy is not 
needed to prevent, diagnose, or treat a medical condition.40 Prior authorization 
mandates establish that physicians must receive the insurer’s permission to prescribe 
a drug in order to have the drug covered by the insurance plan.41 Quantity limits restrict 
the amount of a particular medication that an insurer will cover over a specific period 
of time (e.g. only thirty pills per month).42 Tiering categorizes drugs into tiers and 
assigns different copayment sums to different drug tiers.43 
The insurer’s bottom line is not the only thing that is hurt by exorbitant drug prices. 
Insurers are likely to shift at least some of the costs to patients, raising their premiums, 
charging higher copayments, and increasing deductibles.44 Therefore, patients 
themselves have much to lose from growing coverage costs. 
In principle, therefore, insurers are justified in pursuing initiatives to control 
expenditures. But cost-reduction measures must be implemented thoughtfully and 
responsibly, and step-therapy may all too often do more harm than good. 
C. Does Step Therapy Reduce Insurers’ Expenses? 
Step therapy aims to reduce insurers’ costs without compromising patient care. 
Whether it consistently does so in practice is debatable. 
Some studies have shown meaningful cost savings. For example, a study of blood 
pressure medications found that a step therapy program saved 13 percent in drug 
costs.45 Likewise, a study involving antidepressants concluded that step therapy 
 
39 Joshua Cohen et al., Clinical and Economic Challenges Facing Pharmacogenomics, 13 
PHARMACOGENOMICS J. 378, 380 (2013); Laura E. Happe, A Systematic Literature Review Assessing the 
Directional Impact of Managed Care Formulary Restrictions on Medication Adherence, Clinical Outcomes, 
Economic Outcomes, and Health Care Resource Utilization, 20 J. MANAGED CARE & SPECIALTY 
PHARMACY 677, 677 (2014). 
40 Janet L. Dolgin, Unhealthy Determinations: Controlling “Medical Necessity”, 22 VA. J. SOC. 
POL’Y & L. 435, 438–43 (2015) (discussing varying definitions of medical necessity). 
41 What Is Prior Authorization, Step Therapy, and Quantity Limit?, EHEALTH MEDICARE 
https://www.ehealthmedicare.com/faq-what-are-prior-authorizations-quantity-limits-and-step-therapy/ 
[https://perma.cc/CP37-H7EK] (last updated May 6, 2017). 
42 Id. 
43 Thomas Reinke, Benefit and Formulary Options Appear in Specialty Pharmacy, MANAGED CARE 
(Jan. 2014), https://www.managedcaremag.com/archives/2014/1/benefit-and-formulary-options-appear-
specialty-pharmacy [https://perma.cc/QD3R-T2S8]. A co-payment is “an amount of money that a person 
with health insurance is required to pay at the time of each visit to a doctor or when purchasing medicine.” 
Co-Payment, MERRIAM-WEBSTER, http://www.learnersdictionary.com/definition/co-payment [https://
perma.cc/Z89E-6MV8] (last visited July 4, 2017). 
44 James D. Chambers, Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-
Effectiveness Analysis in the USA?, 32 PHARMACOECON. 729, 732 (2014). The premium is the price that 
individuals pay for insurance. Premium, MERRIAM-WEBSTER, https://www.merriam-webster.com/
dictionary/premium [https://perma.cc/AM35-YUGR] (last visited July 4, 2017). For a definition of co-
payment, see supra MERRIAM-WEBSTER, note 43. A deductible is the amount of money the insured 
individual has to pay before the insurer pays the remaining costs of care. Deductible, MERRIAM-WEBSTER, 
https://www.merriam-webster.com/dictionary/deductible [https://perma.cc/ARE6-4GPK] (last visited July 
4, 2017). 
45 Krista Yokoyama et al., Effects of a Step-Therapy Program for Angiotensin Receptor Blockers on 
Antihypertensive Medication Utilization Patterns and Cost of Drug Therapy, 13 J. MANAGED CARE & 
SPECIALTY PHARMACY 235, 242 (2007). 
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generated savings of nine percent.46 A literature review published in 2011 concluded 
that step therapy generally led to statistically significant savings in drug costs, though 
this was not clearly true in the case of antipsychotics.47 Furthermore, step therapy 
policies for nonsteroidal anti-inflammatory drugs and proton pump inhibitors48 
reduced drug costs without causing an increase in consumption of other medical 
services.49 
Other studies, however, cast doubt on whether step therapy achieves significant 
overall expense reductions. A 2010 article that analyzed 15 prior studies confirmed 
that step therapy lowered drug costs for insurers.50 However, it concluded that it 
generally does not reduce, and may even increase, overall health care expenditures.51 
The researchers explained that patients subject to step therapy restrictions often stop 
taking medication or underutilize it, a phenomenon that can explain why drug costs 
drop while other health care costs rise as a patient’s condition goes untreated.52 
Several additional studies support the conclusion that step therapy is often 
unsuccessful in reducing long-term medical costs. A study focusing on treatment for 
attention deficit hyperactivity disorder concluded that step therapy resulted in no 
overall cost difference but did cause patients to experience treatment delays and to 
underutilize needed drugs.53 A study of a step therapy policy involving Pregabalin, a 
nerve pain medication, found that the policy decreased use of Pregabalin but did not 
reduce total health care costs for patients.54 An economic model designed to determine 
the cost implications of a generic step therapy program for selective serotonin reuptake 
inhibitors (SSRIs) to treat anxiety disorders predicted an adverse cost outcome.55 Drug 
costs would decrease by $0.26 per patient per month but medical costs would increase 
by $0.32 per patient per month.56 
 
46 Jeffrey D. Dunn, Utilization and Drug Cost Outcomes of a Step-Therapy Edit for Generic 
Antidepressants in an HMO in an Integrated Health System, 12 J. MANAGED CARE & SPECIALTY 
PHARMACY 294, 298 (2006). 
47 Brenda R. Motheral, Pharmaceutical Step-Therapy Interventions: A Critical Review of the 
Literature, 17 J. MANAGED CARE & SPECIALTY PHARMACY 143, 143 (2011). 
48 These drugs reduce gastric acid production. See Rena Yadlapati & Peter J. Kahrilas, When Is Proton 
Pump Inhibitor Use Appropriate? 15 BMC MED. 36, 36 (2017), https://bmcmedicine.biomedcentral.com
/articles/10.1186/s12916-017-0804-x [https://perma.cc/GXW3-TRQF] (explaining what a proton pump 
inhibitor is). 
49 Motheral, supra note 47, at 143. 
50 Rashad I. Carlton, Review of Outcomes Associated With Formulary Restrictions: Focus on Step 
Therapy, 2 AM. J. PHARMACY BENEFITS 50, 56–7 (2010). 
51 Id. 
52 Id. 
53 Brandon T. Suehs et al., Impact of a Step Therapy for Guanfacine Extended-Release on Medication 
Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD, 21 J. 
MANAGED CARE & SPECIALTY PHARMACY 793, 801 (2015). 
54 Margarita Udall, Impact of a Step-Therapy Protocol for Pregabalin on Healthcare Utilization and 
Expenditures in a Commercial Population, 16 J. MED. ECON., 784, 784 (2013). 
55 Patt Ellen Panzer et al., Implications of an SSRI Generic Step Therapy Pharmacy Benefit Design: 
An Economic Model in Anxiety Disorders, 11 AM. J. MANAGED CARE S370, S370 (2005). 
56 Id. at S375–76. 
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It is worth emphasizing that step therapy has the potential to severely exacerbate 
health problems.57 As noted above, patients who do not receive their drug of choice 
may stop taking medication or take it only intermittently, and thus their health may 
decline.58 Moreover, physicians may have good reasons to select a particular drug for 
a patient. A different (cheaper) medication may be less effective for a patient or cause 
debilitating side effects.59 
For example, Dr. Benjamin Kopp, a pediatric pulmonologist, relates: “I have 
prescribed certain pulmonary medications for a toddler, only to have the health insurer 
insist on a lower cost medication that is designed for a teenager. This shows me the 
decisions about step therapy requirements do not involved pediatricians, asthma 
specialists, and pharmacists who know the most about the medications.”60 Dr. Kopp 
further asserts that switching a child who was stable on one drug to a different asthma 
drug can cause complications and hospitalizations.61 
The same is true for many other illnesses. In the case of Parkinson’s disease, patients 
and their physicians must carefully weigh the benefits and risks of various drug options 
because medications can cause hallucinations, extreme fatigue, compulsive and 
impulsive behavior, gastrointestinal problems, and more.62 Patients have different 
levels of tolerance for these side effects, and some patients wish to avoid the risk of 
certain side effects at all costs and choose their medication accordingly. 
At times, even switching from a brand name to a generic of the same drug can have 
adverse consequences because of lower efficacy of the generic drug, allergic reactions, 
or patients’ unwillingness to take a new pill that looks different from the one to which 
they are accustomed.63 In reality, generics are not an exact duplicate of the original, 
brand name drug.64 The Food and Drug Administration (FDA) acknowledges that it is 
“aware that there are reports noting that some people may experience an undesired 
effect when switching from a brand-name drug to a generic formulation or from one 
 
57 Joseph Burns, Is Step Therapy a Move In the Wrong Direction?, MANAGED CARE (Jan. 2017), 
https://www.managedcaremag.com/archives/2017/1/step-therapy-move-wrong-direction [https://perma.cc/
CX74-QH2Y]. 
58 Panzer et al., supra note 55, at S372; Arthur Lazarus, Formulary Restrictions Sometimes Harm 
Patients, MANAGED CARE (Oct. 2004), https://www.managedcaremag.com/archives/2004/10/formulary-
restrictions-sometimes-harm-patients [https://perma.cc/54K9-2UTF] (“In the mentally ill, lack of 
appropriate care can also trigger a downward spiral that ends in homelessness or incarceration.”). 
59 Nayak & Pearson, supra note 3, at 1780. 
60 Benjamin Kopp, Opinion, Step Therapy Can Disrupt Best Care for Children’s Health, 
CLEVELAND.COM (June 4, 2017), http://www.cleveland.com/metro/index.ssf/2017/06/step_therapy_can
_disrupt_best.html. [https://perma.cc/7AN7-M2YR]. 
61 Id. 
62 Medications for Motor Symptoms, MICHAEL J. FOX FOUND., https://www.michaeljfox.org
/understanding-parkinsons/living-with-pd/topic.php?medication-motor-symptoms [https://perma.cc/3AJL-
7HWP] (last visited Dec. 29, 2017). 
63 Fischer & Avorn, supra note 26, at 802; Evan H. Langdon, Switching to Generic: The Need for 
Physician and Patient Consent when Substituting Antiepileptic Medication, 25 J. CONTEMP. HEALTH L. & 
POL’Y 166, 180–85 (2008). 
64 Katherine Eban, Are Generics Really the Same as Branded Drugs? FORTUNE (Jan. 10, 2013), 
http://fortune.com/2013/01/10/are-generics-really-the-same-as-branded-drugs/ [https://perma.cc/GWV7-
DWFB]. 
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generic drug to another generic drug.”65 Problems may arise because of quality 
discrepancies among different manufacturers. For example, in 2007 FDA noted 
variations among levothyroxine pills66 produced by different pharmaceutical 
companies.67 Because of concerns about the stability of the drug, FDA required that 
the potency of levothyroxine products degrade by no more than five percent over their 
shelf lives.68 Likewise, a study of the antipsychotic drug olanzapine found 
significantly lower concentrations of the medicine in patients who had switched from 
the brand name to the generic form of the drug.69 It is also noteworthy that generic 
drugs need not contain the same inactive ingredients70 as brand name products,71 so 
patients who tolerated the original drug well may have an adverse reaction to an 
inactive component of the generic substitution.72 
In addition, patients who have to try multiple drugs sequentially before being 
approved for the doctor’s drug of choice may suffer symptoms of drug withdrawal and 
find it difficult to adjust to new medications.73 This is true both for patients who 
initially took the doctor’s recommended drug but were later subjected to step therapy 
requirements and for those who immediately were denied coverage and may try 
several less costly drugs with which they are dissatisfied before requesting a step 
therapy waiver. The Mayo Clinic lists the possible symptoms of antidepressant 
withdrawal (especially if the drug is stopped too quickly) as follows: anxiety, insomnia 
or vivid dreams, headaches, dizziness, tiredness, irritability, flu-like symptoms, 
including achy muscles and chills, nausea, electric shock sensations, return of 
 
65 Gary Stoller, Can The FDA Adequately Police Generics?, CONN. HEALTH I-TEAM (July 12, 2015), 
http://c-hit.org/2015/07/12/can-the-fda-adequately-police-generics/ [https://perma.cc/7SAV-CUES]. 
66 Levothyroxin is used to treat hypothyroidism (diminished or absent thyroid function). Questions 
and Answers on Levothyroxine Sodium Products, FOOD & DRUG ADMIN. (Oct. 3, 2007), 
https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm16
1266.htm [https://perma.cc/88XY-Z47C]. 
67 Id. 
68 Id.; see also, Michael Bihari, Brand Name and Generic Levothyroxine: Is There a Difference 
between Brand Name and Generic Thyroid Drugs?, VERYWELL, (May 28, 2017), https://www.verywell.
com/levothyroxine-brand-name-vs-generic-versions-1124055 [https://perma.cc/SCU3-33M8]. 
69 Domenico Italiano et al., Generic Olanzapine Substitution in Patients with Schizophrenia: 
Assessment of Serum Concentrations and Therapeutic Response After Switching, 37 THERAPEUTIC DRUG 
MONITORING 827, 827 (2015). 
70 Inactive ingredients are components of a drug that do not increase or affect its therapeutic action. 
Examples are binding materials, dyes, preservatives, and flavoring. Inactive Ingredients, DRUGS.COM 
https://www.drugs.com/inactive/ [https://perma.cc/48WC-GEWJ] (last visited July 4, 2017). 
71 Generic Drug Facts, FOOD & DRUG ADMIN., https://www.fda.gov/drugs/resourcesforyou/
consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm167991.htm [https://perma.cc/
ZU6U-YKHT] (last updated June 28, 2016); Eban, supra note 64. 
72 Rong-Kun Chang et al., Generic Development of Topical Dermatologic Products: Formulation 
Development, Process Development, and Testing of Topical Dermatologic Products, 15 AM. ASS’N 
PHARMACEUTICAL STUD. J. 41, 45 (2013) (“Special attention should be paid to the use of fragrance in the 
formulation, because 1% of the general population suffers from fragrance allergies”). 
73 Antidepressant Withdrawal: Is There Such a Thing?, MAYO CLINIC (Jan. 16, 2016), 
http://www.mayoclinic.org/diseases-conditions/depression/expert-answers/antidepressant-withdrawal/faq-
20058133 [https://perma.cc/G35A-BY6B]; Panzer, supra note 55, at S372 (discussing the risks of therapy 
change and discontinuation of treatments for anxiety and depression). 
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depression symptoms.74 All of these can be debilitating for patients who are trying to 
work and lead normal lives. 
Thus, step therapy may often save costs in the very short term but increase costs in 
the long term because of complications, health deterioration, and the patient’s need to 
seek more and more medical care in order to find relief.75 Some insurers may ignore 
the risk of long-term consequences in hope that when these materialize, the patient 
will be working for a different employer with a different policy76 or will have turned 
65 and enrolled in Medicare. But ignoring the risks of step therapy is bad policy for 
patients, health care providers, and the American public at large. 
II. LEGAL, ETHICAL, AND POLICY IMPLICATIONS OF STEP 
THERAPY 
Beyond the possibility of poor health outcomes, step therapy raises several legal 
and ethical concerns. First, insurers may not be transparent about step therapy 
requirements. Second, the one-size-fits-all approach is in tension with the emerging 
trend of precision medicine. Third, insurers may apply the policy in a discriminatory 
fashion that violates federal anti-discrimination mandates. 
A. Lack of Transparency 
Transparency is a core value in health care.77 As the American Health Policy 
Institute explains, “[i]n a fully transparent market, measures that disclose the relative 
cost, quality and customer experience for all elements of the health care supply chain 
would be publicly available.”78 Full transparency would allow consumers to become 
more informed purchasers of health plans and health care services and to demand 
market accountability.79 Without transparency it is nearly impossible “to create a 
rational marketplace in which those who provide superior value are rewarded with 
more business, and those who don’t suffer the consequences.”80 
Assuming that Andy’s experience is representative, patients often have no idea that 
their insurer has implemented a step therapy program and remain ignorant of which 
drugs are subject to it.81 The news that an insurer has refused to pay for a prescribed 
 
74 MAYO CLINIC, supra note 73. 
75 Burns, supra note 57. 
76 Younger workers are especially likely to change jobs frequently. See Heather Long, The New 
Normal: 4 Job Changes by the Time You’re 32, CNN (Apr. 12, 2016), http://money.cnn.com
/2016/04/12/news/economy/millennials-change-jobs-frequently/index.html [https://perma.cc/U9YV-
G5NM]. 
77 STEVE WETZELL, TRANSPARENCY: A NEEDED STEP TOWARDS HEALTH CARE AFFORDABILITY 1 
(2014), http://www.americanhealthpolicy.org/Content/documents/resources/Transparency%20Study%201
%20-%20The%20Need%20for%20Health%20Care%20Transparency.pdf [https://perma.cc/ZAH2-97
WB]. 
78 Id. at 2. 
79 Id. at 4. 
80 Id. 
81 See supra notes 28–29 and accompanying text. 
2018 STEP THERAPY 49 
drug comes as an unwelcome surprise for the patient and prescribing provider, who 
must decide whether to fight the decision or opt for another treatment.82 
Moreover, patients may find that busy medical practices are less than enthusiastic 
about engaging in combat with insurers over denials, an activity for which they do not 
directly get paid.83 A 2011 Government Accountability Office report indicated that 
between 11 and 24 percent of claims and preauthorization requests were denied in the 
three states that were studied.84 Health care providers, therefore, may feel 
overwhelmed by requests for assistance with patient appeals. 
Full transparency about step therapy requirements may enable individuals to choose 
more wisely among different health plans. Admittedly, however, many will not have 
a choice because the majority of employers offer only one insurance plan.85 Even those 
whose employers offer several options may find that all plans are served by the same 
PBM. In fact, three large PBMs, ExpressScripts, CVSHealth (also known as CVS 
Caremark), and OptumRx control approximately 80 percent of the market.86 
At the very least, however, transparency will enable patients and their doctors to 
make more informed decisions about medical care. When physicians and patients 
initially decide on a course of treatment, they must be aware of any limitations that the 
insurer is likely to impose in order to avoid any harmful treatment delays or 
disruptions. 
B. At Odds with Precision Medicine Approach 
Precision medicine can be defined as an “approach for disease prevention and 
treatment that takes into account individual differences in lifestyle, environment, and 
biology.”87 President Obama’s Precision Medicine Initiative, launched in January of 
2015, has fueled precision medicine,88 and emerging resources such as genetic 
technologies, large-scale biologic and electronic health record databases, and 
 
82 Linda Berthold, Health Insurance Claim Denied? Don’t Despair. Fight Back., HUFFINGTON POST 
(Aug. 21, 2011), http://www.huffingtonpost.com/linda-bergthold/health-insurance-claim-de_b_881538.
html [https://perma.cc/PGE5-QWTU]; David Lazarus, How to Fight Back When an Insurer Denies Your 
Healthcare Claim, L.A. TIMES (Jan. 17, 2017), http://www.latimes.com/business/lazarus/la-fi-lazarus-
winning-insurance-appeals-20170117-story.html [https://perma.cc/9M33-REPU]. 
83 PFIZER, supra note 16. 
84 GOV’T ACCOUNTABILITY OFFICE, PRIVATE HEALTH INSURANCE: DATA ON APPLICATION AND 
COVERAGE DENIALS (Mar. 17, 2011), http://www.gao.gov/new.items/d11268.pdf [https://perma.cc/44Z4-
B6R7]. Of the six states on which the report focused, only three captured this data, namely, California, 
Maryland, and Ohio. Id. at 3, 17. 
85 KAISER FAMILY FOUND. & HEALTH RES. & EDUC. TR., 2016 EMPLOYER HEALTH BENEFITS 
SURVEY 72 (Sept. 14, 2016), http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-
Annual-Survey [https://perma.cc/5D6F-BJSU] (“Most firms that offer health benefits offer only one type of 
health plan (83%)” and that “[l]arge firms are more likely to offer more than one plan type than small 
firms.”). 
86 State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces: Hearing 
Before the Subcomm. on Regulatory Reform, Commercial and Antitrust Law of the H. Comm. on the 
Judiciary, 114th Cong. 25 (2015) (statement of David A. Balto); Wapner, supra note 1 (stating that the three 
PBMs “control an estimated 80 to 85 percent of the market”). 
87 About the All of Us Research Program, NAT’L INSTS. HEALTH, https://allofus.nih.gov/about/about-
all-us-research-program [https://perma.cc/US6Q-3779] (last visited June 16, 2017). 
88 See Fact Sheet: President Obama’s Precision Medicine Initiative, WHITE HOUSE OFF. PRESS 
SECRETARY (Jan. 30, 2015), https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sheet-
president-obama-s-precision-medicine-initiative [https://perma.cc/W6HC-4VNS]. 
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advanced computational tools make precision medicine a promising approach.89 The 
Trump administration continues to support the initiative and calls it the All of Us 
Research Program.90 
Precision medicine aims to enable physicians to tailor treatment to patients’ 
attributes and characteristics.91 Thus, physicians may be able to match treatments to 
patients based on factors such as genetic variations, microbiome composition,92 
medical histories, lifestyles, and diet.93 Precision medicine is already improving cancer 
treatments as physicians have begun to test patients and their tumors for particular 
genetic markers to determine what treatment, if any, is appropriate.94 For example, the 
breast cancer drug trastuzumab (Herceptin) has been found to work only for women 
whose tumors have a particular genetic profile called HER-2 positive, and lung cancer 
patients whose tumors are positive for EGFR mutations receive the drugs gefitinib 
(Iressa) and erlotinib (Tarceva) that target this mutation.95 Precision medicine has 
yielded benefits in other areas as well, such as treatments for cystic fibrosis and 
reproductive health.96 
By contrast, step therapy constitutes a one-size-fits-all approach. Insurers require 
that, as a rule, doctors prescribe a particular medication before turning to more 
expensive alternatives.97 In some cases, such mandates may prevent physicians from 
harnessing new knowledge derived from precision medicine research and customizing 
treatment protocols to fit their patients’ particulars. Such inflexibility could ultimately 
 
89 Francis S. Collins & Harold Varmus, A New Initiative on Precision Medicine, 372 N. ENGL. J. 
MED. 793, 793 (2015); Larry J. Jameson & Dan L. Longo, Precision Medicine—Personalized, Problematic, 
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realistic. Michael J. Joyner & Nigel Paneth, Seven Questions for Personalized Medicine, 314 J. AM. MED. 
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diseases and identify novel therapeutic targets for some conditions, the promise of improved risk prediction, 
behavior change, lower costs, and gains in public health for common diseases seem unrealistic.”). 
90 All of Us Research Program, NAT’L INSTS. HEALTH, https://allofus.nih.gov/ [https://perma.
cc/F8GR-L2SK] (last visited July 15, 2017) (explaining that “[t]he mission of the All of Us Research 
Program is to accelerate health research and medical breakthroughs, enabling individualized prevention, 
treatment, and care for all of us). 
91 The Precision Medicine Initiative, WHITE HOUSE, https://obamawhitehouse.archives.
gov/node/333101 [https://perma.cc/XYX5-FTUY] (last visited June 15, 2017); see, e.g., Xiwen Ma et al., 
Personalized Effective Dose Selection in Dose Ranging Studies in STATISTICAL APPLICATIONS FROM 
CLINICAL TRIALS AND PERSONALIZED MEDICINE TO FINANCE AND BUSINESS ANALYTICS 91, 91 (Jianchang 
Lin et al. eds. 2016) (aiming to “identify subgroups with enhanced benefit/risk profiles with appropriate 
doses”); Ilya Lipkovich et al., Tutorial in Biostatistics: Data-Driven Subgroup Identification and Analysis 
in Clinical Trials, 36 STAT. MED. 136, 136 (2017) (introducing a “general framework for evaluating 
predictive biomarkers and identification of associated subgroups”). 
92 Data & Samples, PERSONAL GENOME PROJECT: HARV. MED. SCH., https://pgp.med.harvard
.edu/data/ [https://perma.cc/8U9J-E9BX] (last visited Dec. 28, 2017). Microbiome data focuses on “the 
types of bacteria in and on a participant’s body.” 
93 WHITE HOUSE, supra note 91. 
94 Collins & Varmus, supra note 89, at 794; Jameson & Longo, supra note 89, at 2229. 
95 Impact of Cancer Genomics on Precision Medicine for the Treatment of Cancer, NAT’L CANCER 
INST. & NAT’L HUMAN GENOME RES. INST., https://cancergenome.nih.gov/cancergenomics/impact 
[https://perma.cc/7TX9-SQBF] (last visited June 16, 2017). 
96 W. Gregory Feero, Introducing “Genomics and Precision Health,” 317 J. AM. MED. ASS’N. 1842, 
1842 (2017). 
97 See supra Part I. A. 
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raise health care costs.98 Some patients may receive therapies that are doomed to be 
suboptimal for them and that doctors versed in up-to-date research outcomes would 
not have prescribed absent step therapy restrictions. 
C. Potential Discrimination 
Step therapy can constitute unlawful discrimination if insurers do not thoughtfully 
select the medications that are subject to this policy. Insurance policies are governed 
by a variety of state and federal laws that protect people with disabilities, including 
the Americans with Disabilities Act of 1990 (ADA)99 and the ACA.100 
Almost half of all Americans are covered by employer-provided health insurance.101 
Title I of the ADA prohibits employers from discriminating against qualified 
individuals because of their disabilities, and this mandate extends to benefits such as 
health insurance.102 Likewise, Title II of the ADA prohibits disability discrimination 
with respect to public services provided by state or local entities,103 and Title III 
governs “public accommodations and services provided by private entities.”104 These 
titles thus apply to insurance policies that individuals obtain through the private market 
or state programs (rather than employers). Note that Medicare and Medicaid are 
federal programs and are covered by Section 504 of the Rehabilitation Act, but this 
law’s anti-discrimination mandate is identical to the ADA’s.105 
 
98 See supra Part I. C. 
99 42 U.S.C. §§ 12101, 12213 (2010). 
100 42 U.S.C. §§ 18001 et seq. (2010). 
101 Health Insurance Coverage of the Total Population, HENRY J. KAISER FAMILY FOUND. (2015), 
http://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colI
d%22:%22Location%22,%22sort%22:%22asc%22%7D [https://perma.cc/T7L4-69Y4] (indicating that 
49% are covered by policies that are provided by employers). 
102 42 U.S.C. § 12112(a) (2010). The provision reads: 
No covered entity shall discriminate against a qualified individual with a disability 
because of the disability of such individual in regard to job application procedures, the 
hiring, advancement, or discharge of employees, employee compensation, job training, 
and other terms, conditions, and privileges of employment. 
103 42 U.S.C. § 12132 (2010) providing that 
No individual shall be discriminated against on the basis of disability in the full and 
equal enjoyment of the goods, services, facilities, privileges, advantages, or 
accommodations of any place of public accommodation by any person who owns, leases 
(or leases to), or operates a place of public accommodation. 
See also 42 U.S.C. § 12131 (defining a “public entity” as including any instrumentality of a state or 
local government). 
104 42 U.S.C. § 12182 (2010). Title III provides that 
No individual shall be discriminated against on the basis of disability in the full and 
equal enjoyment of the goods, services, facilities, privileges, advantages, or 
accommodations of any place of public accommodation by any person who owns, leases 
(or leases to), or operates a place of public accommodation. 
Title III “public accommodations” include banks, insurance offices, private educational institutions, 
sales establishments, service establishments, and many other private entities. 42 U.S.C. § 12181(7) (2010); 
see also Sharona Hoffman, AIDS Caps, Contraceptive Coverage, and the Law: An Analysis of the Federal 
Anti-Discrimination Statutes’ Applicability to Health Insurance, 23 CARDOZO L. REV. 1315, 1330–33 
(2002) (discussing the applicability of the ADA’s Title I and Title III to insurance policies). 
105 29 U.S.C. § 794 (2010). The provision reads: 
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The ADA includes a provision that specifically addresses insurers.106 Section 501(c) 
permits insurers to underwrite, classify, or administer risks and to establish the terms 
of bona fide benefit plans in a manner that is not inconsistent with state law.107 
Nevertheless, it prohibits insurers from adopting practices that are “a subterfuge to 
evade the purposes” of the law.108 As I have argued in prior scholarship, Section 501(c) 
obligates insurers “to provide a cost-based justification for discriminatory benefit 
limitations or exclusions and provides a defense only for those who can do so.”109 
Consequently, insurers who select particular conditions for step therapy but exclude 
others to which step therapy could apply could be violating the ADA’s anti-
discrimination mandate. For example, insurers might implement a step therapy 
requirement for anti-depressants but not for diabetes or asthma, and this choice could 
constitute discrimination against mental health patients. Indeed, a 2015 Connecticut 
report (that did not focus specifically on step therapy) found that the state’s largest 
managed care insurers denied approximately one in 12 initial requests for mental 
health services, a rate that represented approximately a 70 percent increase between 
2013 and 2014.110 By contrast, during the same two years, the denial rate for overall 
health services claims declined slightly.111 To avoid liability, insurers should be able 
to articulate actuarial and medical reasons for the structure of their step therapy 
programs. To that end, they might require that patients first try (or switch to) an 
inexpensive drug only in cases in which there is strong evidence that the inexpensive 
medication, for most patients, is at least as effective as more costly alternatives, unless 
the physician can identify specific reasons for an exemption (e.g. an allergy or prior 
history of failure with the drug).112 
The ACA likewise has an anti-discrimination provision. Section 1557 of that law 
prohibits discrimination on the basis of race, color, national origin, sex, age, or 
disability in health programs or activities that receive federal financial assistance or 
are run by a federal executive agency.113 Thus, the ACA’s anti-discrimination mandate 
 
No otherwise qualified individual with a disability in the United States . . .  shall, 
solely by reason of his or her disability, be excluded from the participation in, be denied 
the benefits of, or be subjected to discrimination under any program or activity receiving 
Federal financial assistance or under any program or activity conducted by any Executive 
agency. 
106 42 U.S.C. § 12201(c) (2010). 
107 Id. 
108 Id. 
109 Hoffman, supra note 104, at 1334. 
110 Lisa Chedekel, Report: Private Insurers Deny More Claims for Mental Health Care, HARTFORD 
COURANT (May 13, 2016), http://www.courant.com/health/hc-insurance-mental-health-20160513-story.
html [https://perma.cc/2WEC-LR5N]. 
111 Id. 
112 See Nayak & Pearson, supra note 3, at 1782–84 (discussing the ethical implications of various 
scenarios in which a trial of inexpensive drug A might be required before approval of expensive drug B). 
113 42 U.S.C. § 18116 (a) (2010). The provision reads: 
[A]n individual shall not, on the ground prohibited under title VI of the Civil Rights 
Act of 1964 (42 U.S.C. 2000d et seq.), title IX of the Education Amendments of 1972 (20 
U.S.C. 1681 et seq.), the Age Discrimination Act of 1975 (42 U.S.C. 6101 et seq.), or 
section 794 of title 29, be excluded from participation in, be denied the benefits of, or be 
subjected to discrimination under, any health program or activity, any part of which is 
receiving Federal financial assistance, including credits, subsidies, or contracts of 
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extends to all insurers that receive federal support such as payments through Medicare 
Part D or the ACA Health Insurance Marketplaces.114 This provision too should limit 
insurers’ ability to pick and choose arbitrarily among health conditions that are subject 
to step therapy protocols. 
The ADA, Rehabilitation Act, and the ACA provide aggrieved individuals with a 
private cause of action.115 Consequently, patients who believe they suffered harm 
because of discriminatory step therapy policies could potentially sue their insurers or 
employers who provided the allegedly discriminatory insurance benefit. 
 
III. STATE AND FEDERAL LEGISLATION AFFECTING STEP 
THERAPY 
The state and federal legislatures have not ignored the difficulties that some patients 
face in obtaining insurance coverage for their treatments. Some states have passed 
laws that specifically address step therapy. Both states statutes and federal law 
establish review mechanisms for insurance coverage denials. This Part analyzes these 
protections and the extent to which they apply to different types of insurance plans. It 
examines state step therapy laws, ERISA, the ACA, and the MMA. 
A.  State Step Therapy Legislation 
The states have begun to respond to the step therapy phenomenon with legislation 
that governs how insurers apply these policies. As of mid-2017, 14 states had passed 
legislation addressing step therapy,116 and at least 12 others had bills under 
consideration.117 
 
insurance, or under any program or activity that is administered by an Executive Agency 
or any entity established under this title 1 (or amendments). 
See also Section 1557 of the Patient Protection and Affordable Care Act, DEP’T HEALTH HUM. SERVS. 
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individuals/section-1557/fs-health-insurance/index.html [https://perma.cc/8M77-2C3A]; see generally 
Health Insurance Marketplace, HEALTHCARE.GOV (June 15, 2017), 
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115 For ADA enforcement provisions, see 42 U.S.C § 12117 (a) (2010) (referring to 42 U.S.C. § 2000e-
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Rights Act of 1964); 42 U.S.C. § 12133 (1990) (referring to the Rehabilitation Act’s 29 U.S.C. § 794a, 
which in turn refers to 42 U.S.C. 2000e–5(f), described above); 42 U.S.C. § 12188(a)(2) (1994) (providing 
for injunctive relief in private suits by affected parties). For the Rehabilitation Act, see 29 U.S.C. § 794a 
(2009) (referring to 42 U.S.C. 2000e–5(f), described above). For the ACA’s enforcement provision, see 42 
U.S.C. § 18116(a) (2010) (stating that the Rehabilitation Act’s enforcement provisions apply to violations 
of the ACA’s Section 1557). 
116 Step Therapy Legislation, AM. ACAD. DERMATOLOGY (June 20, 2017), https://www.aad.org/
advocacy/state-policy/step-therapy-legislation [https://perma.cc/8DCN-SYHV]. The states are Arkansas, 
California, Connecticut, Iowa, Illinois, Indiana, Kentucky, Louisiana, Maryland, Missouri, Mississippi, 
New York, Washington, and West Virginia. 
117 Id. The states are Florida, Georgia, Massachusetts, Maine, Minnesota, New Mexico, Ohio, Oregon, 
Rhode Island, Texas, Utah, and Virginia. 
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No state law prohibits step therapy requirements altogether.118 Instead, the statutes 
establish step therapy exemptions, require expedited review of physicians’ requests 
for waivers, and/or limit the duration of step therapy protocols.119 
Some provisions are brief and offer little guidance. For example, Arkansas requires 
only a “clear and convenient process to expeditiously request an override” of step 
therapy requirements,120 and California mandates that such requests be handled in the 
same manner as requests for prior authorization.121 
Other states have more detailed provisions that place restrictions upon insurers. 
Illinois has enacted a typical step therapy statute. It requires insurers to approve or 
deny requests for exemptions within 72 hours of receiving the request and to provide 
an explanation and information regarding alternative drugs and appeals in case of 
denial.122 It further provides that: 
(c) A step therapy requirement exception request shall be approved if: 
(1) the required prescription drug is contraindicated; 
(2) the patient has tried the required prescription drug while under the patient’s 
current or previous health insurance or health benefit plan and the prescribing provider 
submits evidence of failure or intolerance; or 
(3) the patient is stable on a prescription drug selected by his or her health care 
provider for the medical condition under consideration while on a current or previous 
health insurance or health benefit plan.123 
Furthermore, approvals must be honored for at least 12 months or until renewal of 
the plan.124 
Mississippi establishes an additional limitation, which is that “[t]he duration of any 
step therapy or fail-first protocol shall not be longer than a period of thirty (30) days 
when the treatment is deemed clinically ineffective by the prescribing practitioner.”125 
If the physician believes, based on sound clinical evidence, that the originally 
 
118 Id. 
119 Nayak & Pearson, supra note 3, at 1779. 
120 ARK. CODE ANN. § 23-99-1115 (c)(1) (2015); see also W. VA. CODE, § 33-16-3aa (2016) 
(requiring a “clear and convenient process to request a step therapy exception determination” that is easily 
accessible on the insurer’s website); WASH. REV. CODE § 69.41.190(2)(c)(iii) (2011) (“[T]he endorsing 
practitioner shall have an opportunity to request as medically necessary, that the brand name drug be 
prescribed as the first course of treatment.”). 
121 CAL. INS. CODE § 10123.197(a) (West 2016); see supra note 41 for explanation of prior 
authorization. 
122 215 ILL. COMP. STAT. ANN. 134/45.1(b)(2) (2018); see also N.Y. PUB. HEALTH LAWS § 4903.3 
(2017) (providing that if “the health of the insured [is]in serious jeopardy without the prescription drug or 
drugs prescribed by the insured’s health care professional, the step therapy protocol override determination 
shall be granted within twenty-four hours of the receipt of information.”). 
123 215 ILL. COMP. STAT. ANN. 134/45.1(c) (2018). For similar statutes, see CONN. GEN. STAT. ANN. 
§ 38a 544(b)(1) (West 2015); IND. CODE § 27-8-5-30(h)(3) (2016); KY. REV. STAT. ANN. § 304.17A –
163(2) (West 2012); LA. REV. STAT. ANN. § 46:460.34 (2014); MD. CODE ANN. INS. § 15-142 (2014); MO 
REV. STAT. § 376.2034 (2016); MISS. CODE ANN. § 83-9-36(1) (2012); N.Y. PUB. HEALTH LAWS § 4903.3-
a-3-c (2017). 
124 215 ILL. COMP. STAT. ANN. 134/45.1(e) (2018). 
125 MISS. CODE ANN. § 83-9-36(2) (2012); see also CONN. GEN. STAT. ANN. § 38a–544(a)(2) (2015) 
(establishing a 60-day limitation); KY REV. STAT. ANN. § 304.17A–163(3) (West 2012). 
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prescribed medication takes longer than 30 days to become effective, the patient may 
be required to take the originally prescribed medication for an additional seven days.126 
For its part, the federal Medicare program also provides guidance regarding step 
therapy. Medicare allows prescribing clinicians to submit a request for an exception 
along with a supporting statement if “the alternative(s) . . . required to be used in 
accordance with step therapy has (have) been or is (are) likely to be less effective or 
have adverse effects.”127 The plan sponsor must then provide notice of its benefits 
decision within 72 hours or 24 hours in the case of expedited requests.128 
B. The ERISA Problem 
ERISA is a federal law that governs benefit plans that are established and 
maintained by employers.129 Employer-provided health plans cover 49 percent of 
Americans and thus are an extremely important component of the insurance 
landscape.130 
ERISA’s preemption clause prohibits insurance enrollees from pursuing state law 
claims and remedies.131 Specifically, it states that ERISA “shall supersede any and all 
State laws insofar as they may now or hereafter relate to any employee [health] benefit 
plan.”132 Consequently, individuals may not bring actions against insurers based on 
tort, contract, and other state common law theories, including lawsuits for harm caused 
by treatment delays associated with step therapy protocols.133 
However, the statute includes a significant preemption exception. ERISA’s savings 
clause provides that ERISA does not preempt state statutes that regulate insurance.134 
Thus, for example, in 1985 the Supreme Court held that a Massachusetts statute 
mandating that group insurance policies provide particular minimum benefits was not 
preempted by ERISA.135 Because of the savings clause, state statutes governing step 
therapy in principle would survive ERISA preemption. 
The savings clause, however, is limited in its reach because of another ERISA 
provision called the “deemer clause.”136 This clause establishes that state laws 
regulating insurance are preempted with respect to self-funded health insurance 
 
126 MISS. CODE ANN. § 83-9-36(2) (2012). 
127 Exceptions, CTRS. MEDICARE & MEDICAID SERVS. (Nov. 29, 2016), https://www.cms.
gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Exceptions.html [https://perma.cc/
LJ7L-69HW]; 42 C.F.R. § 423.578(b) (2016). 
128 42 C.F.R. §§ 423.568(b), 423.572(a) (2016). 
129 Health Plans & Benefits: ERISA, DEP’T LABOR (June 22, 2017), https://www.dol.gov/general/
topic/health-plans/erisa [https://perma.cc/J8Y3-MPZW]. 
130 HENRY J. KAISER FAMILY FOUND., supra note 101. 
131 29 U.S.C. § 1144(a) (2010). 
132 Id. 
133 Cromwell v. Equicor-Equitable HCA Corp., 944 F. 2d 1272, 1275–76 (6th Cir. 1991); Sharona 
Hoffman, A Proposal for Federal Legislation to Address Health Insurance Coverage for Experimental and 
Investigational Treatments, 78 OR. L. REV. 203, 241–42 (1999). 
134 29 U.S.C. § 1144(b)(2)(A) (2010) (“Except as provided in subparagraph (B), nothing in this 
subchapter shall be construed to exempt or relieve any person from any law of any State which regulates 
insurance . . . .”). 
135 Metropolitan Life Ins. Co. v. Massachusetts, 471 U.S. 724 (1985). 
136 See id. at 735 n. 14. 
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plans.137 Employers with self-funded plans collect premiums and pay all medical 
claims themselves, though they may use a third party to do administrative work for the 
plan.138 Step therapy statutes and other state health insurance laws, therefore, cannot 
be enforced with respect to self-funded plans. According to the Henry J. Kaiser Family 
Foundation, in 2016, 61 percent of workers were enrolled in self-funded health plans, 
which are particularly popular among large companies.139 Consequently, the majority 
of individuals with employer-provided health plans cannot benefit from the protection 
of state step therapy laws. 
C. Other Legislative Protections 
Fortunately, all insured individuals are entitled to a review process for decisions 
with which they disagree. This right is furnished by ERISA and by the ACA. 
ERISA requires that covered insurers afford participants whose medical claims are 
denied a “full and fair review” of adverse decisions.140 Federal regulations provide 
detailed guidance concerning such appeals, which may consist of two different levels 
of review.141 Because this right is created by federal law (not state law), anyone 
enrolled in an employer-provided plan is entitled to a review of claim denials, 
including individuals in self-insured health plans and those in states without step 
therapy statutes.142 
The ACA also addresses health insurance appeals, and unlike ERISA, this federal 
law applies to all health insurance consumers, whether or not their policies are 
provided by employers.143 The provision requires that at a minimum, insurers do the 
following: 1) have an internal claims appeals process; 2) provide an easily understood 
notice to enrollees regarding internal and external review opportunities and any 
available assistance for these processes; and 3) permit enrollees to review their files, 
present evidence and testimony, and enjoy continued coverage until their appeals are 
decided.144 
It is important to note that the ACA mandates that insurers offer not only internal 
reviews but also external ones.145 External reviews are performed by independent third 
parties that are not associated with the health insurance plan.146 
 
137 29 U.S.C. § 1144(b)(B) (2010). 
138 Self-Insured Plan, HEALTHCARE.GOV (June 23, 2017), https://www.healthcare.gov/glossary/self-
insured-plan/ [https://perma.cc/M37A-8Z72]. 
139 HENRY J. KAISER FAMILY FOUND., 2016 EMPLOYER HEALTH BENEFITS SURVEY−SECTION TEN: 
PLAN FUNDING (Sept. 14, 2016), http://www.kff.org/report-section/ehbs-2016-section-ten-plan-funding/. 
[https://perma.cc/5NDG-XSQP]. 
140 29 U.S.C. § 1133 (2010). 
141 29 C.F.R. § 2560.503-1(h) (2016); Benefit Claims Procedure Regulation FAQs, DEP’T LABOR (June 
23, 2017), https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/faqs/benefit-
claims-procedure-regulation [https://perma.cc/2339-9HEL]. 
142 See supra Part III. B (explaining ERISA preemption). 
143 42 U.S.C. § 300gg-19 (2010); NAT’L CONFERENCE OF STATE LEGISLATURES, RIGHT TO HEALTH 
INSURANCE APPEALS PROCESS, (Feb. 2011), http://www.ncsl.org/documents/health/hrhealthinsurapp.pdf 
[https://perma.cc/Y2CQ-58HG]. 
144 42 U.S.C. § 300gg-19(a) (2010). 
145 Id. at § 300gg-19(b). 
146 External Review, HEALTHCARE.GOV (June 26, 2017), https://www.healthcare.gov/glossary/
external-review/ [https://perma.cc/6AXK-W6CW]. 
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External reviews must comply with state external review laws that at the very least 
include “the consumer protections set forth in the Uniform External Review Model 
Act promulgated by the National Association of Insurance Commissioners.147 “If the 
state has not established an appropriate external review process148 or the plan is self-
insured and thus not subject to state laws regulating insurance, the insurer must offer 
an external review process consistent with guidance from the Secretary of Health and 
Human Services.149 
Medicare also enables participants to appeal unfavorable decisions.150 Pursuant to 
the MMA, it establishes a five-level appeal process for those who disagree with 
coverage decisions. The steps include: 1) redetermination from the plan; 2) review by 
an independent review entity; 3) a hearing before an administrative law judge; 4) 
review by the Medicare Appeals Council; and 5) judicial review by a federal district 
court.151 
Patients’ success rates on appeal are encouraging. According to a 2011 federal 
government report, insurance denial reversals ranged between 39 and 59 percent on 
internal appeal, with an additional 23 to 54 percent reversed or revised as a result of 
external appeals.152 The numbers vary significantly by state.153 The report’s authors 
noted that they could not determine an overall appeal rate for claim denials, but data 
from Ohio indicated that in the first quarter of 2010, patients internally appealed only 
0.5 percent of coverage denials.154 It is unclear why patients appealed so infrequently. 
While some may not have been upset by adverse decisions, it is likely that many others 
did not know that appealing was an option or did not have the mental ability or energy 
to initiate appeals. It is possible that news stories about insurance appeals in more 
recent years have raised the appeal figure.155 
As helpful as review processes may be for some patients, they can extend over 
several months. For services not yet received, such as a more expensive drug in a step 
 
147 42 U.S.C. § 300gg-19(b)(1) (2010); NAT’L ASS’N OF INS. COMM’R, UNIFORM HEALTH CARRIER 
EXTERNAL REVIEW MODEL ACT (2010), http://www.naic.org/documents/committees_b_uniform_health
_carrier_ext_rev_model_act.pdf [https://perma.cc/JAB9-QN89]. 
148 See Affordable Care Act: Working with States to Protect Consumers, CTRS. MEDICARE & 
MEDICAID SERVS., https://www.cms.gov/CCIIO/Resources/Files/external_appeals.html [https://perma.cc/
6HWE-P2JT] (last updated Nov. 14, 2016) (listing the states and categorizing the types of external reviews 
they offer). 
149 42 U.S.C. §§ 300gg-19(b)(2)(A)–(B). 
150 42 U.S.C.A. §§ 1395w-104(f)–(h); 42 C.F.R. § 423.562 (2016). 
151 Appeals if You Have Medicare Prescription Drug Coverage, MEDICARE.GOV 
https://www.medicare.gov/claims-and-appeals/file-an-appeal/prescription-plan/prescription-drug-
coverage-appeals.html [https://perma.cc/6SQK-M3M6] (last visited July 13, 2017). 
152 GOV’T ACCOUNTABILITY OFFICE, supra note 84, at 23–24. 
153 Id. 
154 Id. at 22, n. 45. The report also noted that “aggregate claim denial rates for the three states that we 
identified as collecting such data ranged from 11 percent in Ohio in 2009 to 24 percent in California in the 
same year.” Id. at 22. 
155 See, e.g., Pauline Bartolone, Patients Often Win If They Appeal A Denied Health Claim, NPR, (Apr. 
14, 2014), http://www.npr.org/sections/health-shots/2014/04/14/302547851/patients-often-win-if-they-
appeal-a-denied-health-claim [https://perma.cc/NRB9-PWX5]; David Lazarus, How to Fight Back when an 
Insurer Denies Your Healthcare Claim, L.A. TIMES (Jan. 17, 2017), http://www.latimes.com/business/
lazarus/la-fi-lazarus-winning-insurance-appeals-20170117-story.html [https://perma.cc/G6V9-QVX7]. 
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therapy program, insurers must complete internal appeals within 30 days.156 Insurers 
can then take up to 60 days after receiving a request to complete an external review.157 
During these months, the health of a patient who is receiving an inexpensive treatment 
that is a poor fit for her may deteriorate significantly. Thus, even if the coverage denial 
is ultimately reversed, the patient may suffer grave consequences from treatment 
delays.158 
The ACA does not create a private cause of action for wrongful claim denials,159 
but ERISA does do so.160 Therefore, as a last resort, after exhausting the administrative 
remedies described above, enrollees covered by ERISA plans can sue insurers to 
recover benefits to which they are entitled under their policies.161 Other monetary 
damages, such as compensatory and punitive damages, are generally not available.162 
Extensive research revealed no cases in which plaintiffs sued because of adverse 
decisions associated with step therapy.163 However, numerous cases involve another 
cost-control strategy: medical necessity determinations.164 A 2003 U.S. Department of 
Health and Human Services report focused on 54 medical necessity cases and found 
that most often, plaintiffs alleged that insurers arbitrarily and unfairly denied them 
coverage while approving claims in equivalent cases.165 According to the report, 
insurers prevailed in 29 lawsuits and had their decisions reversed in 25 instances.166 
Litigation is expensive and can occupy many months if not years. It is an ineffectual 
tool for obtaining swift overrides of step therapy policies. However, it can be helpful 
 
156 Appealing a Health Plan Decision: Internal Appeals, HEALTHCARE.GOV https://www.healthcare
.gov/appeal-insurance-company-decision/internal-appeals/ [https://perma.cc/D8D7-RGUU] (last visited 
June 26, 2017). 
157 Appealing a Health Plan Decision: External Review, HEALTHCARE.GOV https://www.healthcare.
gov/appeal-insurance-company-decision/external-review/ [https://perma.cc/GL4K-JPHY] (last visited June 
26, 2016). 
158 See Kling-Levine, supra note 7 (relating the author’s experience with step therapy for ulcerative 
colitis); Kopp, supra note 60 (discussing a pediatric pulmonologist’s frustration with step therapy for 
children’s asthma treatments); see also infra notes 7–12 and accompanying text. 
159 Letter from United States Government Accountability Office to Congressional Recipients 
regarding Causes of Action under the Patient Protection and Affordable Care Act (Mar. 23, 2012) (“[W]e 
do not believe that the implementation of the provisions identified in section 3512 of PPACA, including the 
development, recognition, or implementation of related guidelines and standards, is likely to give rise to 
new causes of action or claims.”); Christine H. Monahan, Private Enforcement of the Affordable Care Act: 
Toward an “Implied Warranty of Legality” in Health Insurance, 126 YALE L. J. 1118, 1123 n. 23 (2017). 
The one exception is the ability to sue for discrimination in violation of Section 1557 of the ACA. See supra 
notes 113–115 and accompanying text. 
160 29 U.S.C. § 1132(a) (2010). 
161 Id.; Miller v. Metropolitan Life Ins. Co., 925 F. 2d 979, 986 (6th Cir. 1991). 
162 Mass. Mutual Life Ins. Co. v. Russell, 473 U.S. 134, 144–48 (1985) (“[W]e do not find in § 409 
express authority for an award of extracontractual damages to a beneficiary.”). 
163 This does not preclude the possibility that there are unreported step therapy cases. 
164 SARAH ROSENBAUM ET AL., MEDICAL NECESSITY IN PRIVATE HEALTH PLANS: IMPLICATIONS FOR 
BEHAVIORAL HEALTH CARE 19–21 (2003). For an explanation of medical necessity determinations, see 
supra note 40 and accompanying text. 
165 Id. at 21. 
166 Id. at 20; see, e.g., Delmarva Health Plan v. Aceto, 750 A.2d 1213, 1218 (Del. Ch. 1999) (holding 
that an insurer must cover a lung transplant). 
2018 STEP THERAPY 59 
for patients who opted to pay for an expensive drug out of pocket after receiving a 
coverage denial and wish to be reimbursed for their costs. 
IV. RECOMMENDATIONS 
Patients and physicians have been vocal in expressing their frustration with step 
therapy.167 At the same time, it is undeniable that health care expenses are spiraling 
upwards, and insurers have good reason to be concerned about treatment costs.168 This 
Part develops a balanced set of recommendations that consider the interests of all stake 
holders. It proposes that 1) all states enact step therapy laws that, at minimum, include 
the elements outlined below; 2) ERISA and the ACA address step therapy programs; 
3) insurers improve transparency by disseminating clear information about step 
therapy requirements in print and on their websites; 4) insurers monitor and 
incorporate up-to-date scientific and financial evidence into their policies; and 5) 
insurers implement step therapy programs in a non-discriminatory way. 
A. All States Should Enact Step Therapy Statutes 
Opponents decry step therapy legislation as an overly-rigid intervention and would 
prefer to be free of legislative constraints.169 In truth, however, it is step therapy itself 
that is inflexible and a “one-size-fits-all” approach. It categorically requires patients 
to take particular drugs before being approved for others, no matter what their personal 
circumstances are.170 
State step therapy statutes constitute a measured response to concerns about step 
therapy.171 They do not prohibit it entirely or subject it to cumbersome requirements. 
Rather, they generally provide patients with an avenue to obtain relief quickly when 
needed without significantly undermining insurers’ decision-making powers. 
All states should enact step therapy statutes. The laws need not be identical but 
should include the following requirements: 
 Approval or denial of requests for exemption within 72 hours of receiving 
the request or 24 hours if the request is urgent and there is serious risk to 
the insured’s health.172 
 Exemptions to be granted in the following circumstances: 
o The drug is contraindicated (inappropriate because of the 
patient’s medical history, attributes, or other circumstances); 
o The patient has previously tried the first-step drug, and the 
prescribing physician submits evidence that the drug was poorly 
tolerated or ineffective (evidence can come in the form of a 
physician statement or notations from the patient’s record). 
 
167 See Kling-Levine, supra note 7; Kopp, supra note 60 (discussing a pediatric pulmonologist’s 
frustration with step therapy for children’s asthma treatments). 
168 See supra Part I. B. 
169 Fischer, supra note 26, at 802. 
170 See supra Part I. A. 
171 See supra Part III. A. 
172 See N.Y. PUB. HEALTH LAWS § 4903 (3) (2017). 
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o The patient is already stable on the drug selected by the 
physician.173 
 Inclusion of a clear explanation and information about appeal mechanisms 
and covered alternative medications when the insurer denies a request for 
exemption.174 
 Approval of drugs for at least 12 months when the insurer grants requests 
for exemption.175 
 A clear definition of what step therapy “failure” means. For example, the 
law may require that patients be approved for the physician’s drug of 
choice if they did not experience adequate improvement or symptom relief, 
as judged by the physician, after 30 days.176 It may also mandate that they 
try only one alternative drug before approval of the physician-
recommended medication.177 
Step therapy laws with lucid guidance will assure physicians that time requesting 
exemptions will be well-spent and assure patients that they can obtain treatments that 
will fit their needs. By requiring timely responses, the proposed legislation will prevent 
harmful treatment delays. Approving exemptions for at least 12 months will save 
patients and physicians from having to submit waiver requests every few months, a 
task that can be stressful and onerous. This may be especially helpful for patients with 
mental health or cognitive difficulties who must ask friends or relatives to assist them 
in interacting with doctors and insurers and may feel uncomfortable burdening these 
advocates repeatedly. 
Clearly defining step therapy failure is also important.178 Insurers should not have 
unlimited discretion to demand that patients try cheaper drugs indefinitely or try 
multiple drugs that do not work well for them. Such trials can severely impact patients’ 
health, comfort, and ability to function.179 State statutes should limit the duration of 
first-step drug trials and the number of drugs that must be taken before approval of the 
physician’s drug of choice. 
A complicating factor is that it is not always clear whether a drug has “failed.” In 
the case of drugs that treat pain, discomfort, or certain mental health problems, success 
is judged by patients’ own assessment of whether they feel better. Does the drug 
relieve the pain? Does the drug adequately reduce the symptoms of Parkinson’s 
disease, such as tremor and rigidity? Is the patient less anxious or depressed? If the 
answers are negative, patients will return to their doctors and seek further care. It is 
therefore important that insurers rely on physicians’ attestations regarding the failure 
of drugs instead of attempting to formulate objective criteria of their own. 
 
173 215 ILL. COMP. STAT. ANN. § 134/45.1(c) (2018). 
174 Id. at § 134/45.1(b)(2). 
175 Id. at 134/45.1(e). 
176 MISS. CODE ANN. § 83-9-36(2) (2012). 
177 See ASSEMBLY, NO. 1832, STATE OF NEW JERSEY, 215TH LEG. § 1.a(2), ftp://www.njleg.
state.nj.us/20122013/A2000/1832_I1.HTM [https://perma.cc/BJ2C-W8MQ]. 
178 See Nayak & Pearson, supra note 3, at 1781 (stating that “what constitutes the failure of the first-
step drug can be one of the most contentious aspects of a step therapy policy.”). 
179 See supra notes 7–12 and accompanying text. 
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B. Federal Law Should Address Step Therapy 
As noted above, state step therapy statutes do not govern employer-provided self-
funded health insurance plans because of ERISA’s deemer clause.180 The majority of 
American workers and their families are enrolled in self-funded plans,181 and thus state 
law does not protect them. Consequently, step therapy provisions should be 
incorporated into federal law as well. 
ERISA itself could address step therapy in its “Claims Procedure” section that 
mandates a “full and fair review” of adverse insurance decisions.182 The provision 
should be detailed and include the requirements described above.183 
While Medicare regulations already provide step therapy guidelines for Medicare 
plans,184 the ACA should do so for all other insurance policies. The law could furnish 
step therapy guidelines in a new subpart of its “Appeals Process” provision.185 
However, given the current Congress’ efforts to repeal the ACA, the law’s future is 
uncertain, and it is unlikely that any of its provisions will be expanded in the near term. 
C. Improving Transparency 
Insurers should be fully transparent about their step therapy requirements and 
should disseminate clear and readable information about them through their websites 
and printed materials. They should keep in mind that 50 percent of adults cannot 
understand a book written at an eighth-grade level, and thus informational materials 
should be written at a sixth-grade reading level.186 Insurers should be careful to educate 
both patients and physicians about step therapy policies. They should also ensure that 
their websites include tools that enable users to search for restrictions that apply to 
particular drugs. Medical appointments will be more productive if physicians and 
patients know to take step therapy requirements into account as they consider 
treatment alternatives. Physicians who feel strongly that specific drugs are best for 
patients despite contrary step therapy constraints could immediately initiate waiver 
requests in order to minimize delays and frustrations (and one hopes they will be 
willing to invest the time in doing so). Physicians who have no objections to insurers’ 
preferences could explain them to patients and tailor their recommendations 
accordingly. 
Existing legislative guidelines already embrace the value of transparency. ERISA 
requires insurers to furnish participants with “summary plan descriptions.”187 The 
 
180 See supra notes 136–139 and accompanying text. 
181 See supra note 139 and accompanying text. 
182 29 U.S.C. § 1133 (2010). 
183 See Part IV. A. 
184 See 42 C.F.R. §§ 423.568(b), 423.572(a), 423.578(b) (2016). 
185 42 U.S.C. § 300gg-19 (2010). Note that federal regulations already require that insurers who 
receive a request to review an adverse coverage decision do so within 72 hours or 24 hours in exigent 
circumstances. 45 C.F.R. §156.122(c)(1)(ii), (2)(iii) (2016). 
186 Staggering Illiteracy Statistics, LITERACY PROJECT FOUND. (last visited July 15, 2017), 
http://literacyprojectfoundation.org/community/statistics/ [https://perma.cc/29Z8-DVAK]; Tiffany M. 
Walsh & Teresa A. Volsko, Readability Assessment of Internet-Based Consumer Health Information, 53 
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provision details the “easily understood”188 information that enrollees must receive 
and could be slightly revised to require specific disclosure of step therapy programs.189 
If the summary plan description is lengthy and participants are unlikely to read it, 
insurers would be wise to highlight the existence of step therapy policies in a separate 
newsletter or brochure. In addition, the information should be posted on user-friendly 
websites. 
Several state laws also address transparency and disclosure by health insurers.190 
For example, a California law requires insurers that use a formulary191 to post the 
formulary on their websites.192 A Colorado statute requires the insurance 
commissioner to develop a website that discloses health insurance price 
information.193 State legislatures could similarly establish disclosure requirements 
regarding step therapy. 
Medicare empowers patients to determine whether specific drugs are subject to 
insurance restrictions, including step therapy, through a simple search on its website. 
It offers a page entitled “2017 Drug Finder: Search for Your Prescription Drug across 
All Medicare Part D or Medicare Advantage Plans.”194 Users can enter the name of 
any drug and obtain a wealth of information about whether and in what manner it is 
covered by various Medicare plans.195 All insurers should enable participants to 
conduct such searches. 
Full disclosure serves not only patients’ interests but also those of insurers. Absent 
sound reasons for disagreement, patients and physicians who are aware of step therapy 
guidelines will comply and save insurers the trouble of processing requests for 
exemption and appeals. By contrast, physicians who cannot easily learn of step therapy 
restrictions are more likely to prescribe medications for which insurers will deny 
coverage. Patients who are disappointed and distressed by insurers’ decisions that are 
contrary to their physicians’ recommendations may then attempt to obtain reversals, 
creating administrative work and costs for insurers. 
D. Monitor and Incorporate Up-to-Date Scientific and 
Financial Evidence 
Insurers should frequently review emerging medical evidence to ensure that their 
step therapy protocols are consistent with patients’ best interests. Step therapy 
requirements should not become ossified and outdated. For example, if precision 
medicine studies reveal that individuals with particular genetic mutations or other 
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characteristics (e.g. age, co-existing diseases, etc.) should take drug B rather than drug 
A, insurers with step therapy programs mandating initial trials of drug A should 
respond quickly and alter their coverage guidelines.196 
Another source of relevant data is comparative effectiveness research.197 This 
research, based on studies that compare drugs, devices, or other medical interventions, 
aims “to inform health-care decisions by providing evidence on the effectiveness, 
benefits, and harms of different treatment options.”198 As just one example, a recent 
study published in JAMA Internal Medicine focused on treatments for clostridium 
difficile infection (a bacterium that causes diarrhea).199 When researchers compared 
the antibiotics vancomycin and metronidazole, they concluded that patients who took 
vancomycin had a significantly reduced risk of death within 30 days, which suggested 
that vancomycin should be used as the initial therapy for patients with severe forms of 
the disease.200 It is obvious that such a finding may require insurers to adjust their step 
therapy requirements. 
Likewise, insurers should review their own financial data to determine whether step 
therapy requirements are cost-effective. If a first-step drug has a high failure rate or 
raises overall costs because patients often seek treatment for side-effects and 
complications, insurers should adjust the requirement in question.201 
To these ends, insurers can use their existing pharmacy and therapeutics (P & T) 
committees.202 Federal regulations detail standards for these committees, relating to 
their membership, conflicts of interest, quarterly meetings, documentation, and other 
obligations.203 P & T committees are tasked with reviewing and approving step therapy 
protocols204 and should be sure to monitor new medical and economic data and modify 
the protocols as appropriate.205 
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E. Avoid Discrimination 
Step therapy policies should be equitable and non-discriminatory.206 This is not to 
say that insurers should subject every possible drug to step therapy requirements to 
avoid allegations of discrimination. Rather, step therapy policies must be thoughtful 
and well-supported by scientific and financial evidence. Thus, if patients question why 
a particular drug is subject to restrictions while others are not, insurers must be able to 
articulate sound justifications for their implementation decisions. 
V. CONCLUSION 
Insurers’ concern about the rapidly rising cost of medical care is warranted, and 
they cannot be condemned for establishing cost-control measures.207 In her best-
selling book, An American Sickness: How Healthcare Became Big Business and How 
You Can Take It Back,208 Elisabeth Rosenthal details myriad reasons for the United 
States’ exorbitant health care prices. She also offers a variety of solutions,209 as have 
many other commentators.210 
Step therapy is an intervention that is favored by the majority of U.S. insurers.211 
Often, patients suffer no ill consequences from step therapy policies. For example, 
many patients tolerate generic drugs just as well as they tolerate brand name drugs.212 
In other instances, however, step therapy promotes neither patient interests nor the 
insurer’s economic goals. Patients may suffer grave harms when they do not receive 
their physician’s drug of choice because of step therapy constraints.213 These can 
include medical complication as well as severely diminished functionality, which in 
turn can result in an inability to work, financial difficulties, depression, and health 
problems stemming from a sedentary and inactive lifestyle.214 Thus, step therapy at 
times is penny wise but pound foolish. 
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This article has argued for a nuanced approach to improving step therapy programs 
and reducing their risks.215 Insurers should establish expeditious and uncomplicated 
waiver mechanisms, guided by state and federal legislation, so that patients who truly 
need a more expensive drug can quickly obtain it and doctors are minimally burdened 
by administrative demands. Insurers must also enhance transparency, respond to 
emerging medical and financial evidence that necessitates policy modifications, and 
be wary of discrimination.216 
Finally, the health insurance industry should conduct further research to determine 
if step therapy is in fact an effective cost reduction tool.217 If the programs’ economic 
benefits do not outweigh the burdens they impose on patients, physicians, and insurers, 
they should be altered or abandoned. Step therapy should not constitute a bludgeon 
that is used against patients and their doctors. Instead, it should be a vehicle for all 
stakeholders to work cooperatively to reduce treatment costs without compromising 
health outcomes. 
 
215 See Part IV. 
216 Id. 
217 Rashad I. Carlton et al., Review of Outcomes Associated with Formulary Restrictions: Focus on 
Step Therapy, 2 AM. J. PHARMACY BENEFITS 50 (2010), http://www.ajpb.com/journals/ajpb/2010
/vol2_no1/review-of-outcomes-associated-with-formulary-restrictions-focus-on-step-therapy 
[https://perma.cc/5ZP2-AUCX]; Motheral, supra note 47, at 143. 
